Chimeric antigen receptor T‐cell therapy for haematological malignancies

Adrian G Selim and Constantine S Tam
Med J Aust 2020; 213 (9): . || doi: 10.5694/mja2.50783
Published online: 21 September 2020

The advent of CAR T‐cell therapy has seen significant improvements in survival and is a potential cure for patients with advanced haematological malignancies

Cancer immunotherapy is a burgeoning field which, in the last decade, has produced unprecedented improvements in outcomes across a variety of advanced malignancies. The eventual translation of decades of research into clinically available immunotherapies stems from the expanded knowledge of the role that the immune system plays in preventing tumour initiation and progression as well as the mechanisms by which tumours learn to evade this immune surveillance.1

  • Adrian G Selim
  • Constantine S Tam

  • Peter MacCallum Cancer Centre, Melbourne, VIC

Competing interests:

Adrian Selim has received honoraria from Novartis. Constantine Tam was a principal investigator on the JULIET study sponsored by Novartis, and receives research funding from Janssen and AbbVie, and honoraria from Janssen, AbbVie, BeiGene, Novartis and Roche.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.